SK bioscience Co.,Ltd.(KR:302440)
â‚©38,500.00+300.00 (+0.79%)
KR:302440
SK bioscience Co.,Ltd. financials statements
â‚©38,500.00
At close:+300.00 (+0.79%)
Want to see KR:302440 full AI Analyst Report?
SK bioscience Co.,Ltd. (302440) Ratios
1 Followers
SK bioscience Co.,Ltd. Ratios
KR:302440's free cash flow for Q3 2026 was ₩-14.85B. For the 2026 fiscal year, KR:302440's free cash flow was decreased by ₩-7.77B and operating cash flow was ₩-7.09B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.82 | 5.08 | 10.20 | 4.69 | 4.00 |
| Quick Ratio | 3.24 | 4.40 | 9.60 | 4.20 | 3.70 |
| Cash Ratio | 0.32 | 1.01 | 0.94 | 0.59 | 0.21 |
| Solvency Ratio | 0.04 | -0.01 | 0.38 | 0.37 | 0.73 |
| Operating Cash Flow Ratio | 0.31 | -0.41 | 0.22 | -0.33 | 1.17 |
| Short-Term Operating Cash Flow Coverage | 27.31 | -18.40 | 0.00 | -1.50 | 9.00 |
| Net Current Asset Value | â‚© 327.84B | â‚© 755.53B | â‚© 1.23T | â‚© 1.38T | â‚© 1.33T |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.14 | 0.01 | 0.05 | 0.05 |
| Debt-to-Equity Ratio | 0.26 | 0.22 | 0.01 | 0.07 | 0.07 |
| Debt-to-Capital Ratio | 0.21 | 0.18 | 0.01 | 0.06 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.21 | 0.18 | 0.00 | 0.00 | 0.02 |
| Financial Leverage Ratio | 1.65 | 1.58 | 1.09 | 1.23 | 1.32 |
| Debt Service Coverage Ratio | -2.33 | 0.26 | 41.83 | 1.77 | 5.98 |
| Interest Coverage Ratio | -16.10 | -37.57 | -3.38 | 46.74 | 138.38 |
| Debt to Market Cap | 0.12 | 0.10 | 0.00 | 0.01 | 0.01 |
| Interest Debt Per Share | 6129.72 | 5135.93 | 286.49 | 1509.43 | 1433.50 |
| Net Debt to EBITDA | -6.04 | -2.21 | -2.45 | -0.65 | 0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 9.13% | 11.58% | 38.38% | 52.46% | 61.39% |
| EBIT Margin | -23.23% | -31.93% | 2.36% | 31.57% | 51.08% |
| EBITDA Margin | -9.26% | -13.53% | 11.77% | 37.53% | 53.07% |
| Operating Profit Margin | -23.23% | -51.74% | -1.28% | 25.18% | 51.05% |
| Pretax Profit Margin | -13.18% | -33.31% | 1.98% | 31.03% | 50.71% |
| Net Profit Margin | -8.62% | -20.14% | 6.04% | 26.81% | 38.23% |
| Continuous Operations Profit Margin | -8.62% | -18.73% | 6.04% | 26.81% | 38.23% |
| Net Income Per EBT | 65.42% | 60.47% | 304.59% | 86.40% | 75.38% |
| EBT Per EBIT | 56.74% | 64.37% | -154.88% | 123.23% | 99.35% |
| Return on Assets (ROA) | -1.90% | -1.89% | 1.20% | 5.72% | 16.83% |
| Return on Equity (ROE) | -3.14% | -2.99% | 1.31% | 7.03% | 22.18% |
| Return on Capital Employed (ROCE) | -5.75% | -5.47% | -0.28% | 6.53% | 28.74% |
| Return on Invested Capital (ROIC) | -3.75% | -3.06% | -0.27% | 5.35% | 20.88% |
| Return on Tangible Assets | -2.03% | -1.98% | 1.22% | 5.77% | 16.97% |
| Earnings Yield | -1.49% | -1.38% | 0.40% | 2.17% | 2.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.90 | 1.42 | 41.41 | 11.54 | 19.30 |
| Payables Turnover | 16.77 | 13.28 | 67.56 | 19.64 | 5.62 |
| Inventory Turnover | 3.13 | 1.12 | 2.82 | 1.16 | 2.66 |
| Fixed Asset Turnover | 0.58 | 0.27 | 1.17 | 1.56 | 4.20 |
| Asset Turnover | 0.22 | 0.09 | 0.20 | 0.21 | 0.44 |
| Working Capital Turnover Ratio | 0.60 | 0.21 | 0.28 | 0.33 | 1.21 |
| Cash Conversion Cycle | 169.41 | 555.27 | 132.70 | 328.11 | 91.39 |
| Days of Sales Outstanding | 74.50 | 257.02 | 8.82 | 31.63 | 18.91 |
| Days of Inventory Outstanding | 116.68 | 325.74 | 129.29 | 315.05 | 137.41 |
| Days of Payables Outstanding | 21.76 | 27.49 | 5.40 | 18.58 | 64.93 |
| Operating Cycle | 191.17 | 582.76 | 138.11 | 346.69 | 156.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1310.72 | -1658.27 | 382.65 | -1628.85 | 7014.30 |
| Free Cash Flow Per Share | -1030.39 | -3889.13 | -273.15 | -2625.90 | 6433.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.56 | -0.74 | 0.58 | -1.63 | 12.07 |
| Capital Expenditure Coverage Ratio | 0.56 | -0.74 | 0.58 | -1.63 | 12.07 |
| Operating Cash Flow Coverage Ratio | 0.22 | -0.33 | 1.43 | -1.10 | 5.05 |
| Operating Cash Flow to Sales Ratio | 0.16 | -0.48 | 0.08 | -0.27 | 0.58 |
| Free Cash Flow Yield | -2.14% | -7.72% | -0.37% | -3.57% | 2.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -67.11 | -71.98 | 251.89 | 46.05 | 48.47 |
| Price-to-Sales (P/S) Ratio | 5.79 | 14.54 | 15.21 | 12.35 | 18.53 |
| Price-to-Book (P/B) Ratio | 2.11 | 2.16 | 3.30 | 3.24 | 10.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -46.78 | -12.96 | -268.35 | -27.99 | 34.98 |
| Price-to-Operating Cash Flow Ratio | 36.77 | -30.39 | 191.56 | -45.12 | 32.08 |
| Price-to-Earnings Growth (PEG) Ratio | -25.96 | 0.21 | -3.08 | -0.70 | 0.05 |
| Enterprise Value Multiple | -68.54 | -109.71 | 126.81 | 32.24 | 34.93 |
| Enterprise Value | 4.13T | 3.97T | 5.52T | 5.53T | 17.22T |
| EV to EBITDA | -68.54 | -109.71 | 126.81 | 32.24 | 34.93 |
| EV to Sales | 6.35 | 14.84 | 14.93 | 12.10 | 18.54 |
| EV to Free Cash Flow | -51.30 | -13.23 | -263.26 | -27.43 | 34.99 |
| EV to Operating Cash Flow | 40.33 | -31.02 | 187.93 | -44.23 | 32.09 |
| Tangible Book Value Per Share | 23571.97 | 24583.94 | 21923.68 | 22466.31 | 20709.16 |
| Shareholders’ Equity Per Share | 22872.63 | 23348.99 | 22216.51 | 22703.30 | 20932.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.35 | 0.44 | -2.05 | 0.14 | 0.25 |
| Revenue Per Share | 8328.77 | 3465.56 | 4817.97 | 5953.48 | 12143.80 |
| Net Income Per Share | -718.26 | -697.93 | 291.00 | 1596.18 | 4642.34 |
| Tax Burden | 0.65 | 0.60 | 3.05 | 0.86 | 0.75 |
| Interest Burden | 0.57 | 1.04 | 0.84 | 0.98 | 0.99 |
| Research & Development to Revenue | 0.15 | 0.27 | 0.23 | 0.13 | 0.05 |
| SG&A to Revenue | 0.07 | 0.15 | 0.07 | 0.06 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -1.79 | 2.55 | 1.31 | -1.02 | 1.51 |
Currency in KRW

